Results of Hematopoietic Stem Cell Transplantation After Treatment With Different High-Dose Total-Body Irradiation Regimens in Five Dutch Centers

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 5, 2008, Pages 1444-1454

  van Kempen Harteveld, M Loes ^a   Brand, Ronald ^b   Kal, Henk B ^a   Verdonck, Leo F ^a   Hofman, Pieter ^a   Schattenberg, Anton V ^c   van der Maazen, Richard W ^c   Cornelissen, Jan J ^d   Eijkenboom, Wil M H ^d   van der Lelie, Johannes P ^e   Oldenburger, Foppe ^e   Barge, Renée M ^b   van Biezen, Anja ^b   Vossen, Jaak M J J ^b   Noordijk, Evert M ^b   Struikmans, Henk ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Dose effect relationships; Hematopoietic stem cell transplantation; Late effects; Total body irradiation; Treatment results

Indexed keywords

BIOTECHNOLOGY; CELLS; COMPUTER OPERATING SYSTEMS; DECISION MAKING; IRRADIATION; MULTIVARIANT ANALYSIS; OSMIUM; RADIATION; RANDOM VARIABLES; REGRESSION ANALYSIS; SHELTERS (FROM ATTACK);

ACUTE LEUKEMIA; AFTER-TREATMENT; BIOLOGICAL EFFECTIVE DOSE (BED); ELSEVIER (CO); END POINT (EP); HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT); HIGH DOSE; MULTIVARIATE ANALYSIS (MVA); NON-HODGKIN'S LYMPHOMA (NHL); OVERALL SURVIVAL (OS); SINGLE DOSE; STEM CELL TRANSPLANTATION;

NATURAL RESOURCES MANAGEMENT;

CYCLOSPORIN; METHOTREXATE; STEROID;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION DOSE; SEX DIFFERENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NETHERLANDS; RADIATION PROTECTION; RECURRENCE; RELATIVE BIOLOGICAL EFFECTIVENESS; SEX FACTORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 47249111368     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.11.072     Document Type: Article

References (39)

1. Gratwohl A., Baldomero H., Passweg J., et al. Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia 17 (2003) 941-959
2. Gratwohl A., Brand R., Frassoni F., et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: An EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 36 (2005) 757-769
3. Bacigalupo A., Sormani M.P., Lamparelli T., et al. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica 89 (2004) 1238-1247
4. Boyiadzis M., and Pavletic S. Haematopoietic stem cell transplantation: Indications, clinical developments and future directions. Expert Opin Pharmacother 5 (2004) 97-108
5. Shank B. Can total body irradiation be supplanted by busulfan in cytoreductive regimens for bone marrow transplantation?. Int J Radiat Oncol Biol Phys 31 (1995) 195-196
6. Dusenbery K.E., Daniels K.A., McClure J.S., et al. Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia. Int J Radiat Oncol Biol Phys 31 (1995) 119-128
7. Blume K.G., Kopecky K.J., Henslee-Downey J.P., et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: A Southwest Oncology Group study. Blood 81 (1993) 2187-2193
8. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17 (1999) 1244-1263
9. Barendsen G.W. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 8 (1982) 1981-1997
10. Steel G.G. Basic clinical radiobiology. 3rd ed. (2002), Arnold, London
11. Thames H.D., and Hendry J.A. Fractionation in radiotherapy (1987), Taylor & Francis, London
12. Kal H.B., van Kempen-Harteveld M.L., Heijenbrok-Kal M.H., et al. Biologically effective dose in total-body irradiation and hematopoietic stem cell transplantation. Strahlenther Onkol 182 (2006) 672-679
13. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. Blood 92 (1998) 1455-1456
14. Clift R.A.F.R., Bryant E., Bearman S.I., et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens. Blood 77 (1991) 1660-1665
15. Girinsky T., Benhamou E., Bourhis J.H., et al. Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies. J Clin Oncol 18 (2000) 981-986
16. Corvo R., Paoli G., Barra S., et al. Total body irradiation correlates with chronic graft versus host disease and affects prognosis of patients with acute lymphoblastic leukemia receiving an HLA identical allogeneic bone marrow transplant. Int J Radiat Oncol Biol Phys 43 (1999) 497-503
17. Loberiza Jr. F.R., Zhang M.J., Lee S.J., et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood 105 (2005) 2979-2987
18. Frassoni F., Labopin M., Powles R., et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 355 (2002) 1393-1398
19. Igaki H., Karasawa K., Sakamaki H., et al. Renal dysfunction after total-body irradiation. Significance of selective renal shielding blocks. Strahlenther Onkol 181 (2005) 704-708
20. Lawton C.A., Cohen E.P., Murray K.J., et al. Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation. Bone Marrow Transplant 20 (1997) 1069-1074
21. Girinsky L., Socié G., Amarguellat H., et al. Consequences of two different doses to the lungs during a single dose of total body irradiation: Results of a randomized study on 85 patients. Int J Radiat Oncol Biol Phys 30 (1994) 821-824
22. Gopal R., Ha C.S., Tucker S.L., et al. Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity. Cancer 92 (2001) 1949-1958
23. Bolwell B.J. Are predictive factors clinically useful in bone marrow transplantation?. Bone Marrow Transplant 32 (2003) 853-861
24. Miller C.B., Piantadosi S., Vogelsang G.B., et al. Impact of age in outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol 14 (1996) 1327-1332
25. Cahn J.Y., Labopin M., Mandelli F., et al. Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: A retrospective analysis of the European Bone Marrow Transplant Group. Blood 85 (1995) 575-579
26. Willemze A.J., Geskus R.B., Noordijk E.M., et al. HLA-identical haematopoietic stem cell transplantation for acute leukemia in children: Less relapse with higher biologically effective dose of TBI. Bone Marrow Transplant 40 (2007) 319-327
27. Belkaçemi Y., Pene F., Touboul E., et al. Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission. Results and prognostic factors in 326 consecutive patients. Strahlenther Onkol 174 (1998) 92-104
28. Lazarus H.M., Perez W.S., Klein J.P., et al. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: A retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol 132 (2006) 755-769
29. Ortega J.J., Diaz de Heredia C., Olive T., et al. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy. Haematologica 88 (2003) 290-299
30. Levine J.E., Harris R.E., Loberiza Jr. F.R., et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101 (2003) 2476-2482
31. Drobyski W.R. The role of allogeneic transplantation in high-risk acute myelogenous leukemia. Leukemia 18 (2004) 1565-15658
32. Gorin N.C., Labopin M., Polge E., et al. Risk assessment in adult acute lymphoblastic leukaemia before early haemopoietic stem cell transplantation with a geno-identical donor: An easy clinical prognostic score to identify patients who benefit most from allogeneic haemopoietic stem cell transplantation. Leukemia 17 (2003) 1596-1599
33. Passweg J., Baldomero H., Chapuis B., et al. Haematopoietic stem cell transplantation in Switzerland. Report from the Swiss Transplant Working Group Blood and Marrow Transplantation (STABMT) Registry 1997-2003. Swiss Med Wkly 136 (2006) 50-58
34. Imamura M., Asano S., Harada M., et al. Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan. Int J Hematol 83 (2006) 164-178
35. Lazarus H.M., and Rowe J.M. Reduced-intensity conditioning for acute myeloid leukemia: Is this strategy correct. Leukemia 20 (2006) 1673-1682
36. Deeg H.J., Maris M.B., Scott B.L., et al. Optimization of allogeneic transplant conditioning: Not the time for dogma. Leukemia 20 (2006) 1701-1705
37. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 19 (2005) 2304-2312
38. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104 (2004) 1550-1558
39. Kojima R., Kami M., Kanda Y., et al. Comparison between reduced intensity and conventional myeloablative allogeneic stem cell transplantation in patients with hematologic malignancies aged between 50 and 59 years. Bone Marrow Transplant 36 (2005) 667-674